>Date: Fri, 26 Mar 2004 15:10:05 -0800
>From: Michael Belkin



Press ReleaseSource: Wyeth Pharmaceuticals

Wyeth Announces Discontinuation of Operations in Marietta, PA
Thursday March 25, 2004 12:00 pm ET

MADISON, N.J., March 25 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a
division of Wyeth (NYSE: WYE - News), announced today that all operations
at its Marietta, Pa. facility will be discontinued effective December 2004.
The site was one of the primary manufacturing facilities for the company,
focusing primarily on biologics and vaccines. Most recently, the site was
primarily involved in manufacturing an investigational influenza vaccine.
Final production of clinical trial materials for this vaccine will be
completed later this year, at which time the facility will no longer be
required for production. Wyeth's business partner will conduct future
commercial production of this vaccine.

Today's announcement will result in a workforce reduction of approximately
440 employees. The company has notified its personnel at the site today and
has outlined available severance packages as well as potential employment
opportunities at other Wyeth sites. Workforce reductions are scheduled to
begin at the site in mid-April.

Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth, has leading
products in the areas of women's health care, cardiovascular disease,
central nervous system, inflammation, hemophilia, oncology, and vaccines.
Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery,
development, manufacturing, and marketing of pharmaceuticals, vaccines,
biotechnology products, and nonprescription medicines that improve the
quality of life for people worldwide. The company's divisions include Wyeth
Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

Source: Wyeth Pharmaceuticals